Cambrex Co. (NYSE:CBM) Expected to Announce Earnings of $0.52 Per Share

Analysts predict that Cambrex Co. (NYSE:CBM) will announce $0.52 earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have made estimates for Cambrex’s earnings. The lowest EPS estimate is $0.49 and the highest is $0.53. Cambrex posted earnings per share of $0.74 in the same quarter last year, which indicates a negative year over year growth rate of 29.7%. The company is expected to announce its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Cambrex will report full year earnings of $2.04 per share for the current financial year, with EPS estimates ranging from $2.02 to $2.08. For the next financial year, analysts forecast that the firm will post earnings of $1.99 per share, with EPS estimates ranging from $1.95 to $2.06. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Cambrex.

Cambrex (NYSE:CBM) last issued its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.10. The firm had revenue of $159.46 million during the quarter, compared to analysts’ expectations of $159.71 million. Cambrex had a return on equity of 12.25% and a net margin of 14.35%. The firm’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.72 EPS.

A number of brokerages recently weighed in on CBM. Zacks Investment Research cut Cambrex from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. Robert W. Baird cut Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 price target for the company. in a research note on Friday, May 3rd. They noted that the move was a valuation call. First Analysis cut Cambrex from a “strong-buy” rating to an “outperform” rating and increased their price target for the company from $45.00 to $55.00 in a research note on Tuesday, May 7th. Finally, ValuEngine upgraded Cambrex from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $47.40.

Shares of NYSE CBM traded down $1.20 during mid-day trading on Friday, reaching $41.41. 211,841 shares of the company were exchanged, compared to its average volume of 171,552. The company has a current ratio of 2.96, a quick ratio of 2.01 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $1.47 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 3.42 and a beta of 2.36. Cambrex has a 1 year low of $33.80 and a 1 year high of $69.43. The business has a 50-day simple moving average of $44.84.

A number of institutional investors have recently added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund raised its stake in Cambrex by 1.8% in the first quarter. Oregon Public Employees Retirement Fund now owns 12,997 shares of the biotechnology company’s stock valued at $505,000 after buying an additional 235 shares during the last quarter. Bridge City Capital LLC raised its stake in Cambrex by 0.5% in the second quarter. Bridge City Capital LLC now owns 51,711 shares of the biotechnology company’s stock valued at $2,421,000 after buying an additional 255 shares during the last quarter. Campbell Newman Asset Management Inc. raised its stake in Cambrex by 2.4% in the first quarter. Campbell Newman Asset Management Inc. now owns 14,486 shares of the biotechnology company’s stock valued at $563,000 after buying an additional 345 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Cambrex by 0.7% in the second quarter. Arizona State Retirement System now owns 52,208 shares of the biotechnology company’s stock valued at $2,444,000 after purchasing an additional 362 shares during the period. Finally, Mason Street Advisors LLC increased its holdings in shares of Cambrex by 3.6% in the first quarter. Mason Street Advisors LLC now owns 10,794 shares of the biotechnology company’s stock valued at $419,000 after purchasing an additional 372 shares during the period.

Cambrex Company Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Featured Story: What is an Initial Public Offering (IPO)?

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.